The future of cardiology (2018-2030): Advanced treatments to combat the global advance of cardiovascular diseases
Clifford M Thornton
New York University, USA
: Int J Cardiovas Res
Abstract
The incidence of cardiovascular diseases (CVDs) is rising globally, and rapidly. As a result, this is not just a health issue, but an economic one as related cost is ballooning to economically unsustainable levels. For example, in the U S, total healthcare expenditures, which are significantly driven by heart disease, are nearing 20% of the total gross domestic national product (GDP). As developing economies experience similar increases in CVDs, it will become more challenging to meet their populations’ health needs while sustaining their economies. Some of the key related statistics: On a worldwide basis, 17.7 million people died from CVDs in 2015; this accounts for 31% of all global deaths, the total global cost of treating CVDs was $863 billion in 2010; this is projected to reach approximately $1,100 billion by 2030, 84 Million people in the USA suffer from some form of CVD, 15.8 million Americans have coronary artery disease (CAD), heart failure affects 5 million USA adults, heart disease and stroke account for approximately $320 billion of direct healthcare costs per year in the USA. My presentation will address the following key questions and issues: What is the current gold standard of care today for each of these heart conditions and what are the 3 leading evolving technologies and related treatments to address these heart diseases through 2030: Coronary artery disease (CAD), heart failure, heart valve disease, cardiac arrhythmias, congenital heart defects. What are the leading medical device companies in each of these areas, what are their product roadmaps, and what evolving and advanced technologies are driving these product strategies? When will we see some of these medical breakthroughs integrated into routine practice? Preventive cardiology: What are some practical, proven, and duplicable?
Biography
Clifford M Thornton is a Cardiovascular Device and Imaging Consultant and Medical Journalist, graduated from Sanford-Brown Institute, Iselin, NJ with a certification in Cardiovascular Technology, 2004 (emphasis on echocardiography and cardiac pathologies), B S Business Admin/Marketing, New York University, Stern School of Business, 1997. He has professional experience as a Program Manager with Lucent Technologies/Avaya, Inc. (Enterprise Networking) and led a custom market research practice as a Sr. Analyst for a Telecommunications Industry Research Firm and Consultancy.
